Added Value Medicines
Research at Intas is ongoing and with some of the best talent in the Pharmaceutical Industry, our scientists regularly come up with innovative ideas to fulfil the unmet needs of the Pharmaceutical Market.
Genito-urinary System
Oncology
Musculo-Skeletal System
Immunosupression & Autoimmune Diseases
Respiratory System
Hormonal System
Dermatology
Cardiovascular System
Nervous System
Added Value Medicines
To view our AVM specific dossier portfolio, Please visit our app.
Please click here
Fixed-dose combination formulation
Fixed-dose combination (FDC) medicines are medicines containing two or more active components in fixed proportions within a single dosage form. Intas technology includes bilayer and multi-layer tablets. FDC products allow to reduce patient pill-burden, making them more convenient for patients and resulting in improved treatment adherence. Aside from well-known generics, Intas has developed new FDCs (e.g WO2021019493) bringing new treatment solutions to the healthcare system.
One example is Rofencol®, a new FDC bilayer tablet which combines a fixed dose of Rosuvastatin and Fenofibrate. The dossier has been approved in Europe and launched in Portugal and Spain.
Sustained Release
Oral sustained release (SR) medicines are helpful in reducing dosing frequency to an extent that once daily dosing is sufficient for therapeutic management. This SR technology also provides an improved product efficacy and safety profile due to its reduced fluctuations in drug plasma concentrations. SR medicines are associated with improved treatment compliance and adherence. This SR technology has enabled Intas to build a pipeline of innovative products (e.g., WO 2018051292 & WO2019016686) such as Meniabet TM XR. For this Added Value Medicine, Intas is planning to perfomr a Clinical Phase-III.
Orally Disintegrating Tablet Technology
This is a drug delivery system designed to provide rapid disintegration of the tablet upon contact with saliva in the mouth. This technology provides a convenient dosage form for patients having impaired swallowing function, patients suffering of drug-induced dysphagia, and in general for paediatric and geriatric patients and for patients having aversion to swallow standard tablets or capsules.
This technology has been applied to our Added Value Medicine, Veloxsol®. Veloxsol® is the first solifenacin ODT marketed in Italy, Spain and Czech Republic.
Effervescent Technology
We have the capability to
develop and large-scale
manufacture effervescent
tablets. This technology has been adapted to several molecules providing quick relief along with pleasant flavouring taste.
Recently, Intas has developed a differentiated technology platform ETNA® (under patent application- WO2021064636). ETNA® technology has allowed
Intas to build a portfolio of innovative sodium-free
effervescent products.
None of the products listed above are available for countries where the offer and/or supply of the product could be deemed an infringement of the intellectual property rights of third parties.
